Nettsider med emneord «Cancer»
The immune system protects us against infection and cancer but may also overreact and cause autoimmune disease. Knowledge of molecular mechanisms regulating immune cell activation and control is needed to understand how autoimmune diseases may be prevented or treated.
The immunology group combines proteomics with molecular and cellular biology to investigate the regulation of innate and adaptive immunity, and pathogenic mechanisms involved in autoimmune disease and cancer.
In an essay published this week on the World Economic Forum's News Agenda, UiO researcher Ishita Barua explains why we should look to Finland when planning for future success.
Professor Stein Kaasa and international partners are among the shortlisted candidates for the Cancer Grand Challenges awards.
There is great interest in artificial intelligence (AI) in health care. A recent paper in Gastroenterology discusses important issues when introducing new technology in medicine.
The focus of the Immunbiology Laboratory is immune receptor biology and how this relates to the molecular mechanisms involved in autoimmune disease and cancer.
Researchers have identified a novel immunotherapy for acute myeloid leukemia (AML). Immune cells are programmed to recognize a mutation found in leukemia patients. The results provide hope for new and effective treatment for the most common form of leukemia in adults.
The torpedoes reside in specific cells of the innate immune system. These cells could be the next breakthrough in cancer treatment.
Risk of colorectal cancer in inflammatory bowel disease
– a multinational cohort study.
Dr. Yuichi Mori, postdoctoral fellow at Clinical effectiveness research group, receives the prestigeous EU Grant the Marie Skłodowska-Curie Actions fellowship.
Professor Steve Bova is a Professor and Group Leader at the Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital in Finland.
He will give a talk titled, 'Leveraging the evolutionary history of metastatic prostate cancer'.
Professor Johanna Olweus has been selected for the final of the Cancer Grand Challenges as part of a global research team. If successful, the team hopes to contribute in giving cancer patients new therapies.